- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Paradigms.
Displaying page 1 of 1.
EudraCT Number: 2007-006303-21 | Sponsor Protocol Number: ATX-101-07-07 | Start Date*: 2008-04-07 | |||||||||||
Sponsor Name:Kythera Biopharmaceuticals, Inc. | |||||||||||||
Full Title: Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms fo... | |||||||||||||
Medical condition: Reduction of subcutaneous fat in the submental area | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023849-30 | Sponsor Protocol Number: CSCAbrein&cognitie1-04 | Start Date*: Information not available in EudraCT |
Sponsor Name:University of Amsterdam | ||
Full Title: The effects of MR and GR blockade on the reconsolidation and extinction of fear memories | ||
Medical condition: Fear conditioning acquisition, reconsolidation and extinction in healthy male subjects. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001212-30 | Sponsor Protocol Number: ECEP-BPD | Start Date*: 2018-09-18 | |||||||||||
Sponsor Name:Central Institute of Mental Health, represented by commercial and administrative Director | |||||||||||||
Full Title: A trial to study effects of a single dose Citalopram on emotion processing in female patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals | |||||||||||||
Medical condition: Borderline Personality Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002701-23 | Sponsor Protocol Number: SK200504, 28.04.2005 | Start Date*: 2005-08-14 |
Sponsor Name:Siegfried Kasper, O.Univ.Prof.Dr.Dr.h.c. | ||
Full Title: Escitalopram versus Citalopram Treatment effects on cortical and subcortical activity assessed by pharmacological fMRI | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001228-20 | Sponsor Protocol Number: CAMG334A2401 | Start Date*: 2019-04-11 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adul... | |||||||||||||
Medical condition: Migraine prevention | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) FI (Completed) GB (GB - no longer in EU/EEA) SK (Completed) PT (Completed) GR (Completed) PL (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001128-30 | Sponsor Protocol Number: BIIT001 | Start Date*: 2008-05-07 |
Sponsor Name:SE Dept. of Psychiatry and Psychotherapy | ||
Full Title: EFFICACY OF SERTINDOLE AS COMPARED TO OLANZAPINE OR RISPERIDONE ON PREATTENTIONAL AND ATTENTION-DEPENDENT FUNCTIONS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA. A COGNITIVE AND FMRI STUDY. | ||
Medical condition: schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005401-28 | Sponsor Protocol Number: AOI2021ME_PICKERING | Start Date*: 2022-01-26 |
Sponsor Name:University Hospital of Clermont-Ferrand | ||
Full Title: Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial | ||
Medical condition: postmenopausal osteoporosis | ||
Disease: | ||
Population Age: Elderly | Gender: Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003117-28 | Sponsor Protocol Number: EPU-P77 | Start Date*: 2014-11-03 | ||||||||||||||||
Sponsor Name: | ||||||||||||||||||
Full Title: Can Methylphenidate (Ritalin) improve memory and attention in mild cognitive impairment? An EEG study | ||||||||||||||||||
Medical condition: memory impairment in patients with Mild Cognitive Impairment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003271-35 | Sponsor Protocol Number: KU-AIM-01-2018 | Start Date*: 2019-01-07 | |||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||
Full Title: STUDY OF ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS | |||||||||||||
Medical condition: Attentional deficits and impulsive behaviour. These symptoms are common in attention deficit hyperactivity disorder, but also other conditions affecting the central nervous system such as Alzheimer... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001453-31 | Sponsor Protocol Number: CONMED3 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Copenhagen University Hospital Rigshospitalet | ||||||||||||||||||
Full Title: Automated pupillometry and NIRS-EEG to detect signatures of consciousness in acute brain injury after apomorphine and methylphenidate stimulation: A placebo-controlled, randomized, cross-over study | ||||||||||||||||||
Medical condition: We investigate the possible effects of commercially available apomorphine and methylphenidate on signatures of consciousness in patients admitted to the ICU with acute disorder of consciousness, us... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006773-38 | Sponsor Protocol Number: TSPOC5FOR2022 | Start Date*: 2022-11-29 |
Sponsor Name:Medizinische Einrichtungen des Berzirks Oberpfalz | ||
Full Title: TSPO ligands in the treatment of depression: proof-of-concept of efficacy and underlying mechanisms of action | ||
Medical condition: Unipolar/bipolar depressive disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000319-21 | Sponsor Protocol Number: ClonDO | Start Date*: 2021-12-20 |
Sponsor Name:Charité – Universitätsmedizin Berlin | ||
Full Title: Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial) | ||
Medical condition: Posttraumatic Stress Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000721-20 | Sponsor Protocol Number: CNTO1959PSO3003 | Start Date*: 2014-10-28 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequat... | |||||||||||||
Medical condition: Moderate to Severe Plaque Type Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003053-25 | Sponsor Protocol Number: 1466 | Start Date*: 2012-06-18 | |||||||||||
Sponsor Name:Research and Enterprise Department | |||||||||||||
Full Title: A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen. | |||||||||||||
Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002699-98 | Sponsor Protocol Number: CB001-OL | Start Date*: 2015-04-14 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: OxLith: Exploration of the short-term physical and psychological effects of lithium in mood instability | |||||||||||||
Medical condition: Bipolar disorder with current mood instability | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002790-94 | Sponsor Protocol Number: 200828 | Start Date*: 2020-09-16 | |||||||||||
Sponsor Name:SLSO | |||||||||||||
Full Title: The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density – A Single Dose Randomized, Double Blind, Placebo-Controlled Phase 2 Positron Emission Tomography Study | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000784-23 | Sponsor Protocol Number: KKS-276 | Start Date*: 2020-11-17 | |||||||||||||||||||||
Sponsor Name:Philipps-Universität Marburg | |||||||||||||||||||||||
Full Title: The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect) | |||||||||||||||||||||||
Medical condition: To unravel the neural correlates of the interaction between positive expectation (high/low) and single dose antidepressant treatment (verum/placebo) with esketamine in patients with major depressiv... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003210-10 | Sponsor Protocol Number: B0451001 | Start Date*: 2009-09-24 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE II OPEN LABEL, MULTICENTER, PROSPECTIVE,RELATED MACULAR DEGENERATION, COMPARATOR STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB TREATMENT OF SUBJECTS WITH CHOROIDAL NEOVASCULARIZATION (MONET... | |||||||||||||
Medical condition: Subfoveal Choroidal Neovascularization (CNV) associated with Age-related Macular Degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) BE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023759-27 | Sponsor Protocol Number: 0431-403 | Start Date*: 2011-02-16 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients Wit... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) SI (Completed) SE (Completed) DE (Completed) FI (Completed) CZ (Completed) HU (Completed) DK (Completed) IT (Completed) LT (Completed) SK (Completed) PL (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005677-23 | Sponsor Protocol Number: CFTY720D2311 | Start Date*: 2013-04-02 | |||||||||||
Sponsor Name:Novartis Farma | |||||||||||||
Full Title: A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly ... | |||||||||||||
Medical condition: Relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) LT (Completed) SK (Trial now transitioned) LV (Ongoing) ES (Ongoing) DE (Trial now transitioned) BG (Completed) PL (Completed) AT (Completed) NL (Completed) SE (Ongoing) GB (GB - no longer in EU/EEA) RO (Trial now transitioned) EE (Completed) FR (Trial now transitioned) HR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
